Effect of Primary Intravitreal Bevacizumab Injection on Stage 3 Retinopathy of Prematurity with Plus Signs
Journal of the Korean Ophthalmological Society
;
: 62-69, 2015.
Article
in Korean
| WPRIM
| ID: wpr-45182
ABSTRACT
PURPOSE:
To evaluate the efficacy and safety of primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs.METHODS:
We reviewed retrospectively the medical records of 30 eyes of 16 patients diagnosed with stage 3 retinopathy of prematurity with plus signs treated with primary intravitreal bevacizumab injection between March 1, 2011 and February 28, 2013 and followed up for at least 9 months.RESULTS:
Mean gestational age was 26 + 4 weeks +/- 11 days and mean birth weight was 822 +/- 251.4 g. The locations of disease were zone II in 24 eyes and zone III in 6 eyes. Intravitreal bevacizumab injection was performed after the mean 1.3 +/- 1 day after plus signs were detected. Mean postconceptional age at treatment was 38 + 2 weeks +/- 16 days. Mean follow-up period was 16.6 +/- 6.9 months. Plus signs started to regress after the mean 4.6 +/- 2.3 days after injection and completely regressed after the mean 24.3 +/- 12.4 days. Cataract extraction was performed in 1 eye due to a cataract that appeared not associated with the injection procedure, but was regarded as a treatment failure. There were no local or systemic complications.CONCLUSIONS:
Primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs demonstrated excellent short-term efficacy and safety.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Birth Weight
/
Cataract
/
Retinopathy of Prematurity
/
Cataract Extraction
/
Medical Records
/
Retrospective Studies
/
Follow-Up Studies
/
Gestational Age
/
Treatment Failure
/
Bevacizumab
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS